Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CARTA: Comprehensive Ablative Radiation Therapy With Avelumab in Merkel Cell Carcinoma
NCT04792073Phase 2Active, not recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Mar 2021
- Primary completion
- Mar 2027
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of avelumab in Merkel cell carcinoma (MCC), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Progression-Free Survival at 12 weeks. Started Mar 2021; status: active, not recruiting.
02
Drugs
avelumab
03
Conditions
Merkel cell carcinoma (MCC)
Beyond the preview
Go deeper on NCT04792073.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04792073.